305 related articles for article (PubMed ID: 20711527)
1. The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy.
Superceanu B; Veldhuyzen van Zanten S; Skedgel C; Shepherd M; Sketris I
Can J Gastroenterol; 2010 Aug; 24(8):481-8. PubMed ID: 20711527
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
[TBL] [Abstract][Full Text] [Related]
3. Co-prescription of gastroprotective agents in patients taking non-selective NSAIDs or COX-2 selective inhibitors: analysis of prescriptions.
Pasina L; Nobili A; Tettamanti M; Riva E; Lucca U; Piccinelli R; Defendi L; Perego L; Lucifora S; Bulla C
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):735-43. PubMed ID: 20979932
[TBL] [Abstract][Full Text] [Related]
4. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs.
Sturkenboom MC; Burke TA; Tangelder MJ; Dieleman JP; Walton S; Goldstein JL
Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1137-47. PubMed ID: 14653834
[TBL] [Abstract][Full Text] [Related]
5. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
Barozzi N; Tett SE
Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
[TBL] [Abstract][Full Text] [Related]
6. Comparison of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors use in Australia and Nova Scotia (Canada).
Barozzi N; Sketris I; Cooke C; Tett S
Br J Clin Pharmacol; 2009 Jul; 68(1):106-15. PubMed ID: 19660008
[TBL] [Abstract][Full Text] [Related]
7. Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada.
Hartnell NR; Flanagan PS; MacKinnon NJ; Bakowsky VS
Am J Geriatr Pharmacother; 2004 Sep; 2(3):171-80. PubMed ID: 15561649
[TBL] [Abstract][Full Text] [Related]
8. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database.
Schnitzer TJ; Kong SX; Mavros PP; Straus WL; Watson DJ
Clin Ther; 2001 Dec; 23(12):1984-98. PubMed ID: 11813933
[TBL] [Abstract][Full Text] [Related]
9. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
Targownik LE; Metge CJ; Leung S; Chateau DG
Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
[TBL] [Abstract][Full Text] [Related]
10. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
11. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110
[TBL] [Abstract][Full Text] [Related]
12. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
13. Underutilization of gastrointestinal prophylaxis in high-risk chronic nonsteroidal anti-inflammatory drug users in Korea.
Kim WY; Lee S; Jun K; Ah YM; Lee JY
Int J Clin Pharm; 2021 Jun; 43(3):645-653. PubMed ID: 33147346
[TBL] [Abstract][Full Text] [Related]
14. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
[TBL] [Abstract][Full Text] [Related]
15. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study.
Johnell K; Fastbom J
Clin Drug Investig; 2008; 28(11):687-95. PubMed ID: 18840011
[TBL] [Abstract][Full Text] [Related]
16. Mitigating GI risks associated with the use of NSAIDs.
Momeni M; Katz JD
Pain Med; 2013 Dec; 14 Suppl 1():S18-22. PubMed ID: 24373106
[TBL] [Abstract][Full Text] [Related]
17. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity.
Yuan JQ; Tsoi KK; Yang M; Wang JY; Threapleton DE; Yang ZY; Zou B; Mao C; Tang JL; Chan FK
Aliment Pharmacol Ther; 2016 Jun; 43(12):1262-75. PubMed ID: 27121479
[TBL] [Abstract][Full Text] [Related]
18. Failure to renew prescriptions for gastroprotective agents to patients on continuous nonsteroidal anti-inflammatory drugs increases rate of upper gastrointestinal injury.
Le Ray I; Barkun AN; Vauzelle-Kervroëdan F; Bardou M
Clin Gastroenterol Hepatol; 2013 May; 11(5):499-504.e1. PubMed ID: 23313838
[TBL] [Abstract][Full Text] [Related]
19. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
20. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
